- Home
- EQR vs RPRX Comparison
EQR vs RPRX Comparison
Compare EQR & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQR | RPRX |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3B | 19.5B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EQR | RPRX |
|---|---|---|
| Price | $59.37 | $46.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $69.42 | $47.75 |
| AVG Volume (30 Days) | 2.0M | ★ 2.9M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.81% | 2.00% |
| EPS Growth | ★ 8.09 | N/A |
| EPS | ★ 2.94 | 1.78 |
| Revenue | ★ $2,701,075,000.00 | $2,378,193,000.00 |
| Revenue This Year | $4.17 | $38.30 |
| Revenue Next Year | $3.10 | $4.80 |
| P/E Ratio | ★ $19.89 | $26.40 |
| Revenue Growth | 4.76 | ★ 5.06 |
| 52 Week Low | $57.57 | $29.66 |
| 52 Week High | $72.40 | $47.86 |
Technical Indicators
Market Signals| Indicator | EQR | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 63.57 |
| Support Level | $59.11 | $35.32 |
| Resistance Level | $60.57 | $47.86 |
| Average True Range (ATR) | 1.19 | 0.78 |
| MACD | -0.17 | -0.07 |
| Stochastic Oscillator | 38.69 | 79.89 |
Price Performance
Historical ComparisonAbout EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 318 apartment communities with over 86,000 units and is developing three additional properties with 935 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.